Furthermore, monoclonal antibodies could be designed to block checkpoint receptors like CTLA-4 or PD-1, which are more abundant in non-translocation-associated sarcomas (such as six of the TCGA subtypes analyzed here, excluding SS). The gene discussed is CTLA4; the disease is sarcoma.